RxDoctor Payments Data

Abbas Rabiei, MD

Internal Medicine · Jupiter, FLNPI 1447242268

Payments from drug & device makers

$11,662in general payments, 2019–2025

Across 428 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Bayer$1K
  • Amgen$1K
  • Otsuka America Pharmaceutical, Inc.$848
  • ANI Pharmaceuticals, Inc.$562
  • Calliditas Therapeutics US Inc.$546
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$11,50199%
  • Education$1611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,662 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$1,024,336
Medicare patients
990
Services billed
8,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$114,627
KerendiaFinerenone104$111,363
FarxigaDapagliflozin Propanediol130$109,683
XphozahTenapanor Hcl22$93,223
EliquisApixaban99$90,621
VelphoroSucroferric Oxyhydroxide14$69,602
MounjaroTirzepatide64$67,567
AuryxiaFerric Citrate12$24,894
JardianceEmpagliflozin32$23,101
Sevelamer Carbonate86$21,375
MyrbetriqMirabegron28$18,675
LokelmaSodium Zirconium Cyclosilicate20$12,977
Repatha SyringeEvolocumab14$11,753
Repatha SureclickEvolocumab13$10,481
Calcitriol466$5,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,915$122,660150 claims
Novo NordiskOzempic$485$114,627109 claims
BayerKerendia$1,395$111,363104 claims
PfizerEliquis, Paxlovid$77$91,989130 claims
Fresenius USA Marketing, Inc.Velphoro$120$69,60214 claims
Lilly USA, LLCMounjaro$283$67,56764 claims
Akebia Therapeutics IncAuryxia$254$24,89412 claims
Boehringer IngelheimJardiance$65$23,10132 claims
ANI Pharmaceuticals, Inc.Valsartan$562$4,960129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →